4.7 Review

Engineering broadly neutralizing antibodies for HIV prevention and therapy

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 103, Issue -, Pages 157-173

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2016.01.013

Keywords

Antibody; Therapy; Prevention; HIV; Effector function; Neutralization

Funding

  1. NIAID NIH [1R01AI102691]
  2. Bill and Melinda Gates Foundation [OPP1114729, OPP1032144]
  3. Bill and Melinda Gates Foundation [OPP1032144, OPP1114729] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

A combination of advances spanning from isolation to delivery of potent HIV-specific antibodies has begun to revolutionize understandings of antibody-mediated antiviral activity. As a result, the set of broadly neutralizing and highly protective antibodies has grown in number, diversity, potency, and breadth of viral recognition and neutralization. These antibodies are now being further enhanced by rational engineering of their anti-HIV activities and coupled to cutting edge gene delivery and strategies to optimize their pharmacokinetics and biodistribution. As a result, the prospects for clinical use of HIV-specific antibodies to treat, clear, and prevent HIV infection are gaining momentum. Here we discuss the diverse methods whereby antibodies are being optimized for neutralization potency and breadth, biodistribution, pharmacokinetics, and effector function with the aim of revolutionizing HIV treatment and prevention options. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available